Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient...

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Migraine attacks frequently cause moderate to severe functional disability.
• Over half of migraine sufferers experience significant limitations during attacks.

Purpose of the Study:

• To compare the efficacy of rizatriptan 10-mg wafer versus usual non-triptan therapies in improving functional disability.
• To assess the impact on triptan-naïve migraine patients' ability to resume normal activities within 2 hours post-treatment.

Main Methods:

• An open-label, prospective study involving 1353 adult migraine patients across 111 neurology clinics.
• Patients treated two migraine attacks: one with usual non-triptan therapy (NSAIDs, analgesics, ergot derivatives) and another with rizatriptan 10-mg wafer.
• Data collected included pain intensity, functional disability at baseline and 2 hours, and time to return to normal function.

Main Results:

• Rizatriptan therapy resulted in a >5-fold greater likelihood of no disability at 2 hours compared to usual non-triptan treatments (OR, 5.68; P < .001).
• Patients treated with rizatriptan were twice as likely to return to normal function (AHR, 2.08; P < .001) and experienced 52% faster return to function.
• A significant majority (78.8%) preferred rizatriptan over their usual therapy, citing faster headache relief and return to normal function.

Conclusions:

• Rizatriptan 10-mg wafer is more effective than usual non-triptan therapies for improving functional disability in migraine patients.
• The study highlights rizatriptan's benefits using patient-centered outcomes like functional disability and treatment preference.
• Findings support rizatriptan as a valuable option for acute migraine management, guiding clinical recommendations.